Look for:

Our offer for

COSMO PHARMACEUTICALS NV


ISIN:
NL0011832936
WKN:
32590356
2024/07/17 08:18:59
Price
72.50 EUR
Difference 0.69% (0.50)

General attributes

ISINNL0011832936
SymbolCOPN
ExchangeMunich
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)1,153 EUR
BenchmarkMSCI WORLD INDEX (STRD, UHD)

Market data

Bid (Bid size)-
Ask (Ask size)-
Open72.50 EUR
High72.50 EUR
Low72.50 EUR
Close (prev. day)72.00 EUR
VWAP77.00 EUR
Volume (pcs)0
Trading volume0.00
Number of trades2
Last size0

Futures and Options

Related Futures15
Related Options-

PDF Downloads

Company report: COSMO PHARMACEUTICALS NVPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/07/17 08:18:59
Price
72.50 EUR
Difference 0.69% (0.50)

General attributes

ISINNL0011832936
SymbolCOPN
ExchangeMunich
CurrencyEUR
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)1,153 EUR
BenchmarkMSCI WORLD INDEX (STRD, UHD)

Market data

Bid (Bid size)-
Ask (Ask size)-
Open72.50 EUR
High72.50 EUR
Low72.50 EUR
Close (prev. day)72.00 EUR
VWAP77.00 EUR
Volume (pcs)0
Trading volume0.00
Number of trades2
Last size0

Performance and Risk

6m1Y3Y
Perf (%)+12.40%+56.93%-11.04%
Perf (abs.)+8.00+26.30-9.00
Beta0.350.620.65
Volatility21.3426.2826.65
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)72.40 EUR (0)
Ø price 30 days | Ø volume 30 days (pcs.)74.12 EUR (2)
Ø price 100 days | Ø volume 100 days (pcs.)72.51 EUR (3)
Ø price 250 days | Ø volume 250 days (pcs.)58.73 EUR (5)
YTD High | date77.00 EUR (2024/04/25)
YTD Low | date55.00 EUR (2024/01/02)
52 Weeks High | date77.00 EUR (2024/04/25)
52 Weeks Low | date36.20 EUR (2023/10/30)

All listings for COSMO PHARMACEUTICALS NV

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Duesseldorf2024/07/1719:3071.00 EUR0.006
FINRA other OTC Issues2024/06/2115:3080.25 USD0.001
Frankfurt2024/07/1717:2070.50 EUR0.007
London Stock Exchange2024/07/1516:5971.00 CHF0.321
Munich2024/07/1708:1872.50 EUR0.002
SIX Swiss Exchange2024/07/1717:3069.90 CHF0.60177
Stuttgart2024/07/1715:4471.00 EUR0.007
Tradegate2024/07/1722:0272.00 EUR0.001
Xetra2024/07/1717:3572.00 EUR0.012

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=21098&ID_TYPE_IMAGE_LOGO=2

Contact Details

COSMO PHARMACEUTICALS NV
- -
Riverside II, Sir John Rogerson's Quay - 2 Dublin
Telefon: +353-1-8170370
Fax: +353-1-8230718
E-mail: -

PDF Downloads

Company report: COSMO PHARMACEUTICALS NVPDF Download

Company Profile

Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.

Members of Management Board

Alessandro Della ChaChairman of Managing Board
Biagio ViganòMember of Executive Committee
Luigi LongoMember of Executive Committee
Marco LecchiMember of Executive Committee
Niall DonnellyMember of Executive Committee
Roberto VillaMember of Executive Committee

Board of directors

Alessandro ChàChairman of Supervisory Board
John OšDeaMember of Supervisory Board
Maria Grazia RoncaroloMember of Supervisory Board
Mauro AjaniMember of Supervisory Board
Niall DonnellyMember of Supervisory Board
Silvana PerrettaMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer